CSR Management

Identifying six priority areas based on our corporate philosophy and Codes of Conduct, and contributing to sustainable social development through business activities

ONO PHARMACEUTICAL Codes of Conduct represent the ideal state of a company from a perspective of a high standard of ethics. They also guide us in acting with respect for human rights of all people, complying with laws and regulations, and striving to maintain fair relations with society in every aspect our business activities.
Placing the ONO PHARMACEUTICAL Codes of Conduct at the foundation of our CSR management, we have cross-checked them against the Seven Core Subjects of ISO 26000, and identified Six Priority Areas for the CSR activities. Based on our Corporate Governance, we have defined the other priority areas as Innovative Pharmaceutical Products, Human Resources and Human Rights, The Environment, Fair Operating Practices, and Society, and we are committed to demonstrating accountability to our stakeholders by disclosing information about our efforts in these areas.
*ISO26000 Comparison Table

CSR Management


  • 1. We will develop safe, high quality and effective drugs that help people have a healthy life, and provide society with them in addition to necessary information.
  • 2. We will act with respect for the human rights of all people in every aspect of our business activities.
  • 3. We will comply with the law in every field of our business activities and strive to maintain fair relationships with society.
  • 4. We will make efforts to conserve the global environment in every field of our business activities.
  • 5. We will strive for highly transparent corporate management and proactively disclose business information.
  • 6. We will seek harmony with society as a corporate citizen.


The international standard on social responsibility for organizations, published by the ISO (International Organization for Standardization, based in Geneva) in November 2010

Corporate Governance

We enforce transparency in our corporate management, and thus enhance our corporate value, by not only complying with laws and regulations but also by strengthening our corporate governance systems.

Innovative Pharmaceutical Products

Through collaboration between all our divisions including research, development, business strategy, manufacturing, safety/quality assurance, and marketing, we are committed to the disease areas where the satisfaction level with the treatment is still low among patients and medical needs are high so that we can bring innovative drugs as soon as possible to patients throughout the world.

Human Resources and Human Rights

ONO believes that “People make the company,” and actively supports the development of individual abilities and positive action taken without fear of failure. We promote efforts to improve safety and health conditions, and to create a working environment where the company and its employees can live in harmony and individual abilities blossom to their full extent.
We also value a society where human rights are fully respected and seek to establish a company with no discrimination.

The Environment

Keeping in mind our corporate social responsibilities for the environment, we promote environmental efforts to realize a global environment rich in natural beauty through environmentally sustainable activities in all areas of business operations.

Fair Operating Practices

We thoroughly implement employee education based on our Codes of Conduct and anti-bribery rules and strengthen compliance to establish and maintain sound, fair and transparent relations with medical professionals and trading partners as well as with government and administrative bodies.


We raise our social value by creating and developing pharmaceuticals that truly benefit patients. We always engage with the community with sincerity and act in harmony with the community as a local corporate citizen.

How to Identify Priority Areas

  • 1. ONO PHARMACEUTICAL Codes of Conduct represent the ideal state of a company from six perspectives based on high ethical standards.
  • 2. We identify the social issues to be considered for CSR management and divide them into those which we are required to address, those for which we should give support, and those for which we can give indirect support.
  • 3. We assess and review those issues in consideration of the progress in addressing them, as well as social demand, to identify any items which we should add or aspects on which we should enhance our efforts.

CSR Promotion Structure

To promote CSR activities, we have the CSR Committee in place, chaired by the Director, Senior Managing Executive Officer. The Committee, which mainly consists of managers from various divisions, deliberates and makes decisions on important issues and subjects in the six priority areas for CSR activities. The activities of the Committee are periodically reported to the management.

Participation in United Nations Global Compact

In November 2017, we participated in the United Nations Global Compact (UNGC), which is composed of 10 principles advocated by the UN concerning human rights, labour, the environment, and anti-corruption. We will comply with relevant laws and disseminate the Ten Principles of the Global Compact through our daily activities to ensure that all employees follow them.

The Ten Principles of the UNGC

《Human Rights》
Principle 1: Businesses should support and respect the protection of internationally proclaimed human rights; and
Principle 2: make sure that they are not complicit in human rights abuses.

Principle 3: Businesses should uphold the freedom of association and the effective recognition of the right to collective bargaining;
Principle 4: the elimination of all forms of forced and compulsory labour;
Principle 5: the effective abolition of child labour; and
Principle 6: the elimination of discrimination in respect of employment and occupation.

Principle 7: Businesses should support a precautionary approach to environmental challenges;
Principle 8: undertake initiatives to promote greater environmental responsibility; and
Principle 9: encourage the development and diffusion of environmentally friendly technologies.

Principle 10: Businesses should work against corruption in all its forms, including extortion and bribery.


Efforts made for Achieving Sustainable Development Goals

Sustainable Development Goals (SDGs), which were adopted at the United Nation Summit in 2015, are the common goals of the international community and consists of 17 goals.


In the SDGs, good health and well-being for all is listed as Goal 3. Under our corporate philosophy "Dedicated to Man's Fight against Disease and Pain," we, as a R&D-oriented company specialized in pharmaceuticals, take offering innovative drugs as an important CSR issue and are making efforts to realize it. Specifying cancer, immunologic diseases, and central nervous diseases as our priority research areas, we will develop original innovative drugs for diseases where medical needs still cannot be met, and contribute to achieving Goal 3: Good health and well-being for all through improving medical access.

As Goal 9, build infrastructure for industrialization and technological innovation is listed. Building a foundation to offer innovative drugs is also important for us. We are proactively working on preparing the groundwork for innovation by promoting research through involvement in the GHIT Fund, and research grants for domestic and overseas researchers funded by the Ono Medical Research Foundation and Ono Pharma Foundation.

As Goal 17, leveraging partnerships to achieve the goals is listed. Offering innovative drugs can be achieved not only by ourselves, but also through various partnerships. We had promoted the development of our original drugs in various fields by leveraging the world's cutting-edge technologies, knowledge and findings even before the term "open innovation" was popularized. At the same time, we also proactively work on the introduction and derivation of new drug candidate compounds. Furthermore, in addition to partnership activities with venture and other pharmaceutical companies, we form partnerships with various stakeholders, such as universities, research institutions, administrations, local communities, and NPOs, and make efforts to resolve issues through open innovation. You can find out more about our major business partners from here.

We are now identifying materiality of our CSR activities, and by the end of FY 2018, we will determine which SDGs we should focus on besides the above three goals.


ISO 26000 Comparison Table

Core subjects Issues Related items
Organizational Governance CSR Management
Corporate Governance Structure
Internal Control System
Corporate Governance Code
Risk Management
Business Continuity Plan (BCP)
Human Rights Due diligence Respect for Human Rights
Diversity Promotion Initiatives
Enhancing Cultivation of Employee-friendly Workplaces
Human rights risk situations
Avoidance of complicity
Resolving grievances
Discrimination and vulnerable groups
Civil and political rights
Economic, social and cultural rights
Fundamental principles and rights at work
Labor Practices Employment and employment relationships Human Resources
Respect for Human Rights
Diversity Promotion Initiatives
Enhancing Cultivation of Employee-friendly Workplaces
Conditions of work and social protection
Social dialog
Health and safety at work
Human development and training in the workplace
The Environment Prevention of pollution Environmental Management
Ongoing Environmental Protection Activities
Environmental Efficiency / Environmental Accounting
Sustainable resource use
Climate change mitigation and adaptation
Protection of the environment, biodiversity and restoration of natural habitats
Fair Operating Practices Anti-corruption ONO’s Ethical System
Compliance Promotion Initiatives
CSR Procurement
Responsible political involvement
Fair competition
Promoting social responsibility in the value chain
Respect for property rights
Consumer Issues Fair marketing, factual and unbiased information and fair contractual practices Key Product Profiles
Status of Development Pipeline
Innovative Pharmaceutical Products
(Research, Licensing, Development, Manufacturing, and Marketing)
Protecting consumers’ health and safety
Sustainable consumption
Consumer service, support, and complaint and dispute resolution
Consumer data protection and privacy
Access to essential services
Education and awareness
Community Involvement and Development Community involvement Various Corporate Social Responsibility Activities (Web-Based Information Dissemination, Initiatives for Medical Advancement, Activities to Support the Health of People)
Activities as a Corporate Citizen
Education and culture
Employment creation and skills development
Technology development and access
Wealth and income creation
Social investment